Top

Published in:

01-07-2012 | Translational Research and Biomarkers

Clinical Significance of Molecular Detection of Matrix metalloproteinase-1 in Bone Marrow and Peripheral Blood in Patients with Gastric Cancer

Authors: Yoshimasa Kosaka, MD, PhD, Koshi Mimori, MD, PhD, Takeo Fukagawa, MD, PhD, Kenji Ishikawa, MD, Tsuyoshi Etoh, MD, PhD, Hitoshi Katai, MD, PhD, Takeshi Sano, MD, PhD, Masahiko Watanabe, MD, PhD, Mitsuru Sasako, MD, PhD, Masaki Mori, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Special Issue 3/2012

Abstract

Purpose

Matrix metalloproteinases are responsible for proteolytic degradation of basement membrane and extracellular matrix. In tumor tissues, elevated expression of matrix metalloproteinase-1 (MMP-1) has been associated with tumor invasion and metastasis. However, little is known about the expression of MMP-1 in peripheral blood (PB) and bone marrow (BM) in gastric cancer patients. Thus, the aim of the present study is to determine MMP-1 messenger RNA (mRNA) expression levels in BM and PB of patients with gastric cancer.

Methods

The study group consisted of 857 patients with gastric cancer (577 males and 280 females) ranging in age from 27 to 87 years (average 61.6 years). MMP-1 mRNA expression levels in BM and PB were evaluated quantitatively by real-time reverse-transcription polymerase chain reaction (RT-PCR).

Results

Expression of MMP-1 mRNA in BM and PB of patients with gastric cancer was significantly higher than in noncancer patients. High levels of MMP-1 mRNA expression were significantly associated with differentiated histology, tumor size, tumor invasiveness, lymph node metastasis, liver metastasis, and clinical stage. Particularly importantly, MMP-1 mRNA expression in PB was an independent factor of distant metastasis.

Conclusions

We disclosed that MMP-1 mRNA expression in peripheral blood and bone marrow of gastric cancer patients was very high, precisely reflecting staging of gastric cancer. MMP-1 mRNA expression in peripheral blood may be a useful marker for distant metastasis in gastric cancer.

Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353: 793–802.PubMedCrossRef

Pantel K, Woelfle U. Micrometastasis in breast cancer and other solid tumors. J Biol Regul Homeost Agents. 2004; 18: 120–5.PubMed

Seeliger H, Spatz H, Jauch KW. Minimal residual disease in gastric cancer. Recent Results Cancer Res. 2003; 162: 79–87.PubMedCrossRef

Vogel I, Kalthoff H. Disseminated tumour cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas. Virchows Arch. 2001; 439: 109–17.PubMedCrossRef

Tsavellas G, Patel H, Allen-Mersh TG. Detection and clinical significance of occult tumour cells in colorectal cancer. Br J Surg. 2001; 88: 1307–20.PubMedCrossRef

Bockmann B, Grill HJ, Giesing M. Molecular characterization of minimal residual cancer cells in patients with solid tumors. Biomol Eng. 2001; 17: 95–111.PubMedCrossRef

Braun S, Pantel K. Micrometastatic bone marrow involvement: detection and prognostic significance. Med Oncol. 1999; 16: 154–65.PubMedCrossRef

Calaluce R, Miedema BW, Yesus YW. Micrometastasis in colorectal carcinoma: a review. J Surg Oncol. 1998; 67: 194–202.PubMedCrossRef

Iinuma H, Okinaga K, Egami H, et al. Usefulness and clinical significance of quantitative real-time RT-PCR to detect isolated tumor cells in the peripheral blood and tumor drainage blood of patients with colorectal cancer. Int J Oncol. 2006; 28: 297–306.PubMed

10.

Mimori K, Fukagawa T, Kosaka Y, et al. Hematogenous metastasis in gastric cancer requires isolated tumor cells and expression of vascular endothelial growth factor receptor-1. Clin Cancer Res. 2008; 14: 2609–16.PubMedCrossRef

11.

Heiss MM, Simon EH, Beyer BC, et al. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol. 2002; 20: 2005–16.PubMedCrossRef

12.

Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Schildberg FW. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg. 1997; 226: 736–44; discussion 744–735.PubMedCrossRef

13.

Heiss MM, Allgayer H, Gruetzner KU, et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med. 1995; 1: 1035–9.PubMedCrossRef

14.

Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays. 1993; 15: 105–11.PubMedCrossRef

15.

Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis. 1992; 10: 145–55.PubMedCrossRef

16.

Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991; 64: 327–36.PubMedCrossRef

17.

Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2: 161–74.PubMedCrossRef

18.

Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001; 17: 463–516.PubMedCrossRef

19.

Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000; 6: 4823–30.PubMed

20.

Shiozawa J, Ito M, Nakayama T, Nakashima M, Kohno S, Sekine I. Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod Pathol. 2000; 13: 925–33.PubMedCrossRef

21.

Kanamori Y, Matsushima M, Minaguchi T, et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res. 1999; 59: 4225–7.PubMed

22.

Ito T, Ito M, Shiozawa J, Naito S, Kanematsu T, Sekine I. Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod Pathol. 1999; 12: 669–74.PubMed

23.

Murray GI, Duncan ME, O’Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol. 1998; 185: 256–61.PubMedCrossRef

24.

Murray GI, Duncan ME, O’Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med. 1996; 2: 461–62.PubMedCrossRef

25.

Nakopoulou L, Giannopoulou I, Gakiopoulou H, Liapis H, Tzonou A, Davaris PS. Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol. 1999; 30: 436–42.PubMedCrossRef

26.

Inoue T, Yashiro M, Nishimura S, et al. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med. 1999; 4: 73–7.PubMed

27.

Airola K, Karonen T, Vaalamo M, et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer. 1999; 80: 733–43.PubMedCrossRef

28.

Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997; 80: 1803–4.PubMedCrossRef

29.

Masuda TA, Inoue H, Sonoda H, et al. Clinical and biological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma: modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res. 2002; 62: 3819–25.PubMed

30.

Mori M, Mimori K, Inoue H, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res. 1995; 55: 3417–20.PubMed

31.

Sasse EA. How to define and determine reference intervals in the clinical laboratory: approved guideline. 2000.

32.

Sugai H, Kono K, Takahashi A, et al. Characteristic alteration of monocytes with increased intracellular IL-10 and IL-12 in patients with advanced-stage gastric cancer. J Surg Res. 2004; 116: 277–87.PubMedCrossRef

33.

Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol. 2004; 15: 139–45.PubMedCrossRef

34.

Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood. 2001; 97: 3658–61.PubMedCrossRef

35.

Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA. 2000; 97: 14608–13.PubMedCrossRef

36.

Beaudry P, Force J, Naumov GN, et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 2005; 11: 3514–22.PubMedCrossRef

37.

Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000; 105: 71–7.PubMedCrossRef

38.

Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964–7.PubMedCrossRef

39.

Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005; 11: 261–2.PubMedCrossRef

40.

Barille S, Collette M, Thabard W, Bleunven C, Bataille R, Amiot M. Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells. Cytokine. 2000; 12: 1426–9.PubMedCrossRef

41.

Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980; 284: 67–8.PubMedCrossRef

42.

Kosaka Y, Mimori K, Fukagawa T, et al. Identification of the high-risk group for metastasis of gastric cancer cases by vascular endothelial growth factor receptor-1 overexpression in peripheral blood. Br J Cancer. 2007; 96: 1723–8.PubMedCrossRef

Title: Clinical Significance of Molecular Detection of Matrix metalloproteinase-1 in Bone Marrow and Peripheral Blood in Patients with Gastric Cancer
Authors: Yoshimasa Kosaka, MD, PhD
Koshi Mimori, MD, PhD
Takeo Fukagawa, MD, PhD
Kenji Ishikawa, MD
Tsuyoshi Etoh, MD, PhD
Hitoshi Katai, MD, PhD
Takeshi Sano, MD, PhD
Masahiko Watanabe, MD, PhD
Mitsuru Sasako, MD, PhD
Masaki Mori, MD, PhD, FACS
Publication date: 01-07-2012
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue Special Issue 3/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-1905-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical Significance of Molecular Detection of Matrix metalloproteinase-1 in Bone Marrow and Peripheral Blood in Patients with Gastric Cancer

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Special Issue 3/2012

Clinicopathological Analysis of β-catenin and Axin-1 in Solid Pseudopapillary Neoplasms of the Pancreas

A Novel Genetically Modified Oncolytic Vaccinia Virus in Experimental Models is Effective Against a Wide Range of Human Cancers

Single Nucleotide Polymorphisms and Haplotypes of MMP-14 are Associated with the Risk and Pathological Development of Oral Cancer

Intraoperative versus Early Postoperative Intraperitoneal Chemotherapy after Cytoreduction for Colorectal Peritoneal Carcinomatosis: an Experimental Study

Increased CD13 Expression Reduces Reactive Oxygen Species, Promoting Survival of Liver Cancer Stem Cells via an Epithelial–Mesenchymal Transition-like Phenomenon

High Expression of Delta-Like Ligand 4 Predicts Poor Prognosis After Curative Resection for Pancreatic Cancer